Lupin Launches FDA-Approved HIV Generic With 180-Day Exclusivity

Lupin launched raltegravir 600 mg tablets in the U.S. as the exclusive first-to-file and is eligible for 180-day generic exclusivity. U.S. annual sales were estimated at $26 million.